SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings from the LIGHTSITE 3B study presented at the ARVO meeting on the long-term use of photobiomodulation in dry age-related macular degeneration.The open-label extension study included 6…
Author: Healio ophthalmology
Office-based surgery offers satisfaction for patients, ‘rebirth’ for surgeons
Office-based surgery started with the idea that patients undergoing cataract surgery should have the same experience as those undergoing LASIK.In 2011, Healio | OSN Refractive Surgery Board Member Jason P. Brinton, MD, was working with Healio | OSN Ref…
Q&A: Collaboration between endocrinologists, ophthalmologists key for thyroid eye disease
In this Healio Video Exclusive, Trevor Angell, MD, speaks with Vivek R. Patel, MD, about how endocrinologists and ophthalmologists can work together when treating thyroid eye disease.Communicating about a patient’s health status during thyroid eye dise…
FDA grants rare pediatric disease designation for Stargardt disease gene therapy
The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 and cone-rod dystrophy 3, according to Ocugen.Ocugen may receive a pri…
Healthy Vision Month focuses on preventing future vision loss
What can people do now to protect their vision in the future? That is the focus of Healthy Vision Month.“Healthy Vision Month in May is a great opportunity for organizations to come together to raise awareness and provide education to the public on a v…
TearCare shows durability in dry eye disease improvement at 24 months
LOS ANGELES — At the American Society of Cataract and Refractive Surgery meeting, Jennifer M. Loh, MD, discussed 24-month data investigating TearCare, a localized heat therapy treatment for dry eye disease, compared with Restasis.Stage 1 of the SAHARA …
Investigational oral therapy improves pancreatic function, symptoms in Wolfram syndrome
An oral therapy to treat Wolfram syndrome significantly improved pancreatic functions and induced improvement in symptoms at 24 and 48 weeks for most participants in a phase 2 trial.There are no FDA-approved treatments for Wolfram syndrome, a rare neur…
Lumify Preservative Free redness-reducing eye drops launch in US
Editor’s note: This is a developing news story. Please check back soon for updates.Bausch + Lomb launched a preservative-free form of Lumify redness-reducing eye drops in the U.S., according to a press release.Lumify Preservative Free is the only prese…
Opt-out cash pay: An old-school option
OK. One last column on the whole “why is my medicine so expensive” thing, and then I am done. Promise.It has come to my attention that one of my Healio | OSN pieces was “borrowed” to support a manufacturer’s cash-pay strategy for its dry eye disease (D…
Man presents with intermittent blurred vision, photophobia
A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, non-small cell lung cancer and ocular hypertension…
FDA approves Susvimo for treatment of diabetic retinopathy
The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in which patients with diabetic retinopathy (DR) who receiv…
Gene therapy for X-linked retinoschisis promising in phase 1/2 trial
A subretinal injection of ATSN-201 gene therapy demonstrated promising results in patients with X-linked retinoschisis in a phase 1/2 clinical trial, according to a press release from Atsena Therapeutics.Part A of the LIGHTHOUSE study evaluated the tol…
VIDEO: Axitinib maintains stable vision in wet AMD in phase 2b trial
SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings presented at the ARVO meeting from a phase 2b study evaluating suprachoroidal axitinib for neovascular age-related macular degeneration.The trial enrolled 60 previously treated patie…
Veligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye disease
ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the THRIVE and THRIVE-2 trials.The 15-week results of the THRIVE trial…
Verana Health launches real-world dataset on cataract surgery
Verana Health launched a real-world dataset on cataract surgery outcomes, according to a press release.“Qdata Cataracts is a unique real-world dataset that enables precise analysis of patients undergoing cataract surgery while also tracking their outco…
Zenlens Chroma HOA scleral contact lenses launched in US
Bausch + Lomb announced the U.S. launch of Zenlens Chroma HOA scleral contact lenses, designed to reduce symptoms such as halos and glare and correct advanced higher-order aberrations, according to a press release.“Using Zenlens Chroma HOA custom techn…
Proposed cuts to SAMHSA, AHRQ could further stress primary care system
Major cuts to some federal health agencies could have a detrimental impact on the everyday work primary care providers do, according to experts.On May 2, the Trump administration released its 2026 budget proposal, sometimes referred to as the “skinny b…
Axenfeld-Rieger syndrome poses challenges in cataract surgery
A century ago, Theodor Axenfeld described a series of patients with congenital abnormalities of the anterior segment of the eye, including anterior displacement of Schwalbe’s line, termed posterior embryotoxon, with anterior iris adhesions.Shortly ther…
VIDEO: Can temporal artery ultrasound replace biopsy in giant cell arteritis?
SEVILLE, Spain — In this Healio Video Perspective, Andrew G. Lee, MD, discusses whether temporal artery ultrasound can be used in place of temporal artery biopsy in the diagnosis of giant cell arteritis.At the Congress on Controversies in Ophthalmology…
Keratoconus treatment a ‘modern-day miracle’ through decades of collaboration
Classic textbooks teach that the incidence of keratoconus is one per 2,000. That would equate to about 170,000 patients with keratoconus in the United States.However, more recent studies suggest the incidence of keratoconus is at least 10 times higher,…